MGMT and glioblastoma: This can be achieved by studying new approaches to systemic management, including agents that act to potentially reverse or modify resistance by targeting GBM stem cells [15,16], or modify response to RT [17] in an effort to link systemic management and RT to both MGMT-dependent and MGMT-independent mechanisms.